Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/professor-tony-mok-honoured-with-the-esmo-lifetime-achievement-award-recognising-his-global-leadership-in-defining-lung-cancer-treatment-standard
https://www.med.cuhk.edu.hk/press-releases/professor-tony-mok-honoured-with-the-esmo-lifetime-achievement-award-recognising-his-global-leadership-in-defining-lung-cancer-treatment-standard
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony Shu Kam MOK, Chairman of the Department of Clinical Oncology and Li Shu Fan Medical Foundation Professor of Clinical Oncology of the Faculty of Medicine at The Chinese University of Hong Kong (CUHK), is bestowed with the European Society for Medical Oncology (ESMO) Lifetime Achievement Award, one of the most prestigious international honours and recognitions given to cancer researchers, for his contribution to and leadership in lung cancer research worldwide. Professor MOK is the first Chinese to receive this Award. He is considered as “a legend in medical oncology” and “the first one to really put in practice personalised medicine in advanced lung cancer”. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. Much of his research has shifted the treatment paradigm and defined the current management of lung cancer.

 

Professor MOK as the World’s First to Put in Practice Precision Medicine in Lung Cancer

Trained in Canada, Professor MOK returned to Hong Kong and joined the Faculty of Medicine at CUHK in 1996. His work encompasses clinical research on oncogene driven lung cancer and the application of immunotherapy.  

 

In the past, the only treatment for advanced lung cancer was chemotherapy, killing both cancer cells and normal cells at the same time. The average survival of these patients was only a few months.  

 

In 2009, Professor MOK published the IRESSA Pan-Asia Study (IPASS), which is a landmark study that established for the first-time targeted therapy as the first-line treatment in adenocarcinoma patients harbouring epidermal growth factor receptor (EGFR) mutation. It proved that targeted therapy in non-smoking Asian adenocarcinoma patients has a higher efficacy than the conventional intravenous chemotherapy. Furthermore, in 2014, Professor MOK published another study proving that molecular targeted therapy is superior to standard first-line chemotherapy in ALK-positive lung cancer patients.  

 

The major breakthroughs in the clinical studies led by Professor MOK have found a new treatment paradigm for mutated lung cancer. Currently, doctors will check for EGFR or ALK mutation before prescribing a customised treatment plan. For patients with EGFR mutation or who are ALK-positive, targeted therapy will be the first-line treatment. This puts personalised medicine into practice which helps cancer patients live better and for longer.  

 

However, when EGFR mutation is being targeted by the therapeutic agent, cancer cells will further mutate, and a new driver oncogene will emerge. This is why patients with EGFR mutation develop resistance after first-line targeted therapy. Professor MOK’s research highlights the need for patients to be continuously monitored on how cancer evolves in their bodies. Once the disease progresses on first-line treatment, further mutation tests should be considered to customise the treatment.

 

Chemotherapy is the current standard treatment if no driver oncogene is found nor appropriate targeted drugs are available. In recent years, immunotherapy has emerged, bringing hopes and more treatment choices to patients. The application of immunotherapy is another focus of Professor MOK’s research interest.  

 

Professor MOK has led multiple multinational studies and contributed to over 220 articles in prestigious international journals, including the New England Journal of Medicine (NEJM) and The Lancet. He transformed the treatment practice for patients whose cancer genes further mutate and develop resistance after first-line EGFR targeted therapy in 2016. This study was selected as one of the ten most “Notable Articles of 2017” by the NEJM.  

 

Honoured as “a Legend in Medical Oncology”, Being the First Chinese to Receive this Honour  

ESMO, one of the leading professional organisations for medical oncology in the world, has recently presented the Lifetime Achievement Award to Professor Tony Mok for his practice changing contribution to lung cancer. This Award is one of the most prestigious international honours and recognitions given to cancer researchers.  

 

Professor MOK said, “I am most grateful and humbled to have been chosen by ESMO to receive this honour. I am deeply indebted to all my local and global collaborators for their selfless support over the past two decades. This Award is not only a significant encouragement to me, but also an acknowledgement of the Asian researchers for their contributions to personalised medicine.”       

 

At the award presentation ceremony, Professor MOK highlighted the significance of “friendship” and “collaboration”. He said, “As a clinician-scientist, my duty is to create hope for patients. My achievement is to create hope with likeminded friends.”

 

Dr. Evandro de AZAMBUJA, Chair of the ESMO Fellowship and Award Committee, lauded Professor MOK’s work and said, “MOK is a legend in medical oncology. He was the first one to really put in practice personalised medicine in advanced lung cancer with the use of targeted therapy. His research has led to a change of treatment paradigm for lung cancer patients and helped define the current practice.”  

 

In addition to presenting the Lifetime Achievement Award to Professor Tony Mok, this year ESMO also honored Professor Jean-Charles Soria, Senior Vice President and Head of the Oncology Innovative Medicines Unit at MedImmune with the ESMO Award; Professor Pasi A. Jänne at Harvard Medical School with the Award for Translational Research; and Dr Margaret Foti, Chief Executive Officer of the American Association for Cancer Research with the Women for Oncology Award.

 

About the European Society for Medical Oncology (ESMO)

With 18,000 members representing oncology professionals from over 150 countries worldwide, the European Society for Medical Oncology (ESMO) is the world’s largest society of reference for oncology education and information. ESMO is committed to offering the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating sustainable cancer care worldwide.

 

Professor Tony MOK (2nd from left), Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology of the Faculty of Medicine at CUHK, is bestowed with the European Society for Medical Oncology (ESMO) Lifetime Achievement Award for his practice changing contribution to lung cancer. Professor Mok is the first Chinese to receive this award. (Photo courtesy of the European Society for Medical Oncology)

Professor Tony MOK (2nd from left), Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology of the Faculty of Medicine at CUHK, is bestowed with the European Society for Medical Oncology (ESMO) Lifetime Achievement Award for his practice changing contribution to lung cancer. Professor Mok is the first Chinese to receive this award. (Photo courtesy of the European Society for Medical Oncology)

 

At the award presentation ceremony, Professor Tony Mok highlighted the significance of “friendship” and “collaboration”. He said, “As a clinician-scientist, my duty is to create hope for patients. My achievement is to create hope with likeminded friends.” (Photo courtesy of the European Society for Medical Oncology)

At the award presentation ceremony, Professor Tony Mok highlighted the significance of “friendship” and “collaboration”. He said, “As a clinician-scientist, my duty is to create hope for patients. My achievement is to create hope with likeminded friends.” (Photo courtesy of the European Society for Medical Oncology)

More Press Releases

CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
CUHK Professor Dennis LO Receives 2021 Breakthrough Prize, an Honour Renowned as the “Oscars of Science”

CUHK Professor Dennis LO Receives 2021 Breakthrough Prize, an Honour Renowned as the “Oscars of Science”

Awards and honors
Insights into B-cells and GPR18 Gene Expression by CU Medicine team  Improve Prediction of Survival in Multiple Cancer Types

Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types

Research
CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

Research
Two CUHK Scholars Named World’s “Top 20 Translational Researchers” Professor Dennis Lo Receiving the Honour for the Third Consecutive Year

Two CUHK Scholars Named World’s “Top 20 Translational Researchers” Professor Dennis Lo Receiving the Honour for the Third Consecutive Year

Awards and honors
Two CUHK Scholars from the Faculty of Medicine Receive Croucher Senior Medical Research Fellowships

Two CUHK Scholars from the Faculty of Medicine Receive Croucher Senior Medical Research Fellowships

Awards and honors
Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Response
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Medicine Professor Juliana Chan Receives International Honour for  Outstanding Research and Care in Diabetes

CUHK Medicine Professor Juliana Chan Receives International Honour for Outstanding Research and Care in Diabetes

Awards and honors
李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

Donation
Professor Francis CHAN as the First Chinese Honoured with the American College of Gastroenterology International Leadership Award 2018

Professor Francis CHAN as the First Chinese Honoured with the American College of Gastroenterology International Leadership Award 2018

Awards and honors
Professor Dennis LO Being Named as World’s “Top Translational Researchers” for Two Consecutive Years

Professor Dennis LO Being Named as World’s “Top Translational Researchers” for Two Consecutive Years

Awards and honors
CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

Health Campaign
CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

Research
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
Two CUHK Medical Professors Winning WuXi PharmaTech Life Science and Chemistry Awards

Two CUHK Medical Professors Winning WuXi PharmaTech Life Science and Chemistry Awards

Awards and honors
CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

Research
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
‘Science is an Integral Part of My Life’ CUHK’s Prof. Dennis Lo Reaps Inaugural Future Science Prize

‘Science is an Integral Part of My Life’ CUHK’s Prof. Dennis Lo Reaps Inaugural Future Science Prize

Awards and honors
CUHK Professor Receives World Honour For Stroke Services Pioneering an Innovative 3-in-1 Multi-Target Therapy to Repair Damaged Brain After Stroke and Enhance Functional Recovery

CUHK Professor Receives World Honour For Stroke Services Pioneering an Innovative 3-in-1 Multi-Target Therapy to Repair Damaged Brain After Stroke and Enhance Functional Recovery

Awards and honors
CUHK Professor Dennis Lo Named ‘Thomson Reuters Citation Laureate’, an Honour Considered as an Index to Predict Nobel Prize Winners

CUHK Professor Dennis Lo Named ‘Thomson Reuters Citation Laureate’, an Honour Considered as an Index to Predict Nobel Prize Winners

Awards and honors
CUHK Professor Dennis Lo Receives Future Science Prize – Life Science Prize, the China's Nobel Prize

CUHK Professor Dennis Lo Receives Future Science Prize – Life Science Prize, the China's Nobel Prize

Awards and honors
CUHK Professor Hui Yao LAN’s Research on Chronic Kidney Disease Wins First Prize in Chinese Medical Science and Technology Award

CUHK Professor Hui Yao LAN’s Research on Chronic Kidney Disease Wins First Prize in Chinese Medical Science and Technology Award

Awards and honors
CUHK Professor Dennis Lo as the First Chinese Honoured with AACC Wallace H. Coulter Lectureship Award

CUHK Professor Dennis Lo as the First Chinese Honoured with AACC Wallace H. Coulter Lectureship Award

Awards and honors
CUHK Professor Diana Lee Inducted as Fellow of American Academy of Nursing

CUHK Professor Diana Lee Inducted as Fellow of American Academy of Nursing

Awards and honors
CUHK Medical Student Wins Grand Prize in FameLab Contest Hong Kong to Compete in FameLab International in UK

CUHK Medical Student Wins Grand Prize in FameLab Contest Hong Kong to Compete in FameLab International in UK

Awards and honors
CUHK Professor Dennis Lo Received International Honour for Pioneering Research in Personalized Medicine

CUHK Professor Dennis Lo Received International Honour for Pioneering Research in Personalized Medicine

Awards and honors
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

Awards and honors
CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

Research

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.